

## Zambia Support for Pentavalent Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Zambia					
<b>2. Grant number:</b> 1821-ZMB-04a-X					
<b>3. Date of Decision Letter:</b> 12 March 2019					
<b>4. Date of the Partnership Framework Agreement:</b> 22 October 2014					
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine					
<b>6. Vaccine type:</b> Pentavalent					
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose(s) per vial, LIQUID					
<b>8. Programme duration<sup>1</sup>:</b> 2005 -2021					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2005-2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	61,462,566 <sup>3</sup>	1,771,500	2,032,500	2,024,500	67,291,066
<b>10. Vaccine introduction grant (in US\$)</b> Not applicable					
<b>11. Product switch grant:</b> Not applicable					
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>					
Type of supplies to be purchased with Gavi funds in each year	2005-2018	2019			
Number of Pentavalent vaccines doses		1,580,700			
Annual Amounts (US\$)	US\$61,462,566 <sup>5</sup>	US\$1,771,500			
<b>13. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.					

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<b>14. Self-procurement:</b> Not applicable			
<b>15. Co-financing obligations:</b> Reference code: 1821-ZMB-04a-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.			
Type of supplies to be purchased with Country funds in each year	2019	2020	2021
Number of vaccine doses	293,900	398,600	472,200
Number of AD syringes	305,700	417,700	494,900
Number of safety boxes	3,375	4,600	5,450
Value of vaccine doses (US\$)	US\$308,495	US\$418,457	US\$495,757
Total co-financing payments (US\$) (including freight)	US\$343,500	US\$465,500	US\$551,500
<b>16. Operational support for campaigns:</b> Not applicable			
<b>17. Additional reporting requirements:</b> Not applicable			
Reports and information	Due dates		
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> </ul> Countries shall report the actual switch date in the first renewal request following the actual implementation.	31 March 2019		
	15 May 2019		
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat		
<b>18. Financial clarifications:</b> Not applicable			
<b>19. Other conditions:</b> The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.			

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
12 March 2019